Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compounds having lipid lowering properties

A technology of mixtures and lipids, applied in the directions of active ingredients of hydroxyl compounds, organic active ingredients, medical preparations containing active ingredients, etc., can solve the problem of lowering cholesterol and other problems that are not mentioned

Inactive Publication Date: 2008-02-27
VITAL HEALTH SCIENCES PTY LTD
View PDF2 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0033] International patent application WO 2004 / 064831 also records tocopheryl phosphate, which mentions that tocopheryl phosphate can inhibit monocyte / macrophage proliferation, smooth muscle cell proliferation, CD36 receptor expression and oxidized LDL uptake, but No mention of lowering blood levels of lipids like cholesterol

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds having lipid lowering properties
  • Compounds having lipid lowering properties
  • Compounds having lipid lowering properties

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0117] This example is used to evaluate the anti-CVD effect of the tocopheryl phosphate mixture in the existing CVD apolipoprotein E (APOE) mouse model. Anti-CVD effects were determined in this case by whether elevated plasma cholesterol, triglyceride and LDL levels were reduced.

[0118] APOE knockout mouse models are widely used in cardiovascular research, which mimic many of the clinical features of some human diseases. APOE knockout mice begin to have elevated circulating lipid levels at approximately 6 months of age. Feeding the mice a high-fat, high-cholesterol diet (that is, 21% fat, 0.15% cholesterol) sharply increased CVD so that relevant symptoms could be observed as soon as possible.

[0119] method

[0120] Animals: Male APOE knockout mice (15-20 g) were obtained from Perth Animal Resource Center, Australia, and provided with pelleted mouse chow containing no vitamin E, 21% fat and 0.15% cholesterol (manufactured by Glen Forrest Stockfeeders, W.A., Australia) ...

Embodiment 2

[0158] This example is used to evaluate the effect of tocopheryl phosphate mixture (TPm) (mono-tocopheryl phosphate and di-tocopheryl phosphate) on the progression of atherosclerotic lesions in male APOE-deficient mice

[0159] method

[0160] 28 mice were divided into 4 groups: 2 control groups, 1 tocopheryl acetate (TA) group (fed at 150 mg TA / kg) and 1 TPm group (fed at 200 mg TPm / kg, containing 7% fat )

[0161] diet:

[0162] "Induction Period" - The Induction Period includes the first 16 weeks of the Treatment Period. During this period, the mice were fed a low vitamin E pelleted rat chow (less than 20 mg vitamin E per gram of food, 7% total fat), modified standard AIN93G rodent chow (SF05-040, Specialtyfeeds, Glen Forrest, WA Australia). The animals in the control group were only fed the above food, while the TA group was fed with TA at a dose of 150 mg / kg, and the TPm group was fed with TPm at a dose of 200 mg / kg. TA and TPm were released at an average dose of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

There is provided a therapy for lowering the blood levels of a lipid selected from the group comprising LDL cholesterol, triglycerides, overall cholesterol and mixtures thereof, the therapy comprising the step of administering an effective amount of one or more phosphate derivatives of one or more electron transfer agents.

Description

technical field [0001] The invention relates to a treatment method for reducing one or more blood lipid levels of LDL cholesterol, triglyceride and total cholesterol by using a modified electron transfer agent. Background technique [0002] When this manual refers to or discusses a certain scientific and technological literature, a certain scientific theory or a certain knowledge point, it does not mean that the scientific and technological literature, scientific theory or knowledge point or any combination thereof has been published and publicly available on the priority date. common knowledge, or related to the process of trying to solve the technical problems involved in this specification. [0003] While the following relates to cardiovascular disease, it is to be understood that this is for illustrative purposes only and that the present invention is equally applicable to any condition associated with elevated lipid levels in addition to cardiovascular disease. [0004...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/355A61K31/375A61K31/07A61P3/10A61P9/10A61P3/06A61P9/00
CPCA61K31/07A61K31/683A61K31/355A61K31/661A61K31/375A61K31/122A61K45/06A61P1/16A61P13/12A61P27/02A61P3/10A61P35/00A61P3/06A61P9/00A61P9/10A61K2300/00A61K31/665
Inventor S·M·韦斯特E·奥古R·利比来凯
Owner VITAL HEALTH SCIENCES PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products